Formulation Development
Adare & Laxxon AnnouNce 3D-Printing Collaboration
Adare Pharma Solutions recently announced a collaboration with Laxxon Medical to provide the pharmaceutical market with cGMP 3D printing capabilities from Adare’s Pessano facility in…
CoreRx, Societal CDMO & Bend Bioscience Unite Under the Bend Bioscience Brand to Provide World Class CDMO Offering
In a significant move, CoreRx, Societal CDMO, and Bend Bioscience have announced their unification under the Bend Bioscience brand. This merger brings together three highly…
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial With First-in-Class Lead Therapeutic Candidate
TransCode Therapeutics, Inc. recently announced dosing of the first two patients in its Phase 1 clinical trial with its lead candidate, TTX-MC138. Several additional patients…
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial for the Treatment of Systemic Lupus Erythematosus
Cullinan Therapeutics, Inc. received Human Research Ethics Committee (HREC) approval in Australia to initiate its global Phase 1 clinical trial to evaluate CLN-978, its CD19xCD3 bispecific…
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b Trial
AC Immune SA recently announced it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a…
ImmuneSensor Therapeutics Granted New US Patent for its Oral cGAS Inhibitors
ImmuneSensor Therapeutics recently announced the United States Patent and Trademark Office (USPTO) has issued US patent No. 12,091,387 containing claims covering compositions of matter and…
Molex Announces Agreement to Acquire the Vectura Group Limited, Expanding its Drug Delivery Capabilities in Inhalation
Molex, a parent to Phillips Medisize, a leader in the design, engineering, and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, recently…
Atsena Therapeutics Receives Orphan Drug Designation for Gene Therapy to Treat X-linked Retinoschisis
Atsena Therapeutics recently announced the US FDA has granted Orphan Drug Designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a best-in-class gene…
Orbis Medicines & Vivtex Form Research & Exclusive Licensing Collaboration
Orbis Medicines recently announced a research collaboration and option to an exclusive license with Vivtex, a biotech company aiming to transform the development of oral…
Serán Bioscience Announces $200-Million Strategic Growth Transaction & Plans for New Commercial Facility
Serán Bioscience recently announced a strategic growth transaction of more than $200 million. Bain Capital Life Sciences led the transaction, while existing investor Vivo Capital…
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Athira Pharma, Inc. recently announced that following the topline data readout from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD)…
Voyager Advances Collaboration With Neurocrine; Third Gene Therapy Development Candidate Selected
Voyager Therapeutics, Inc. recently announced that the joint steering committee with its collaborator Neurocrine Biosciences, Inc. has selected a development candidate in a gene therapy…
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients With Glioblastoma
Shuttle Pharmaceuticals Holdings, Inc. recently announced it has entered into agreements with two additional site locations to administer the Phase 2 clinical trial of Ropidoxuridine…
Vivtex Enters New Research Agreement With Equillium to Develop GI-targeted Formulations for its First-in-Class Oral, Bi-Specific Peptide Therapy
Vivtex Corporation recently announced it has entered a research and licensing agreement with Equillium, Inc., a clinical-stage biotechnology company developing novel therapeutics to treat severe…
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting With FDA & Plan to Initiate a Phase 3 Clinical Trial
Nanoscope Therapeutics Inc. recently announced a productive End-of-Phase 2 (EOP2) meeting with the US FDA for its clinical program evaluating MCO-010 for the treatment of…
Vico Therapeutics Announces Positive Interim Phase 1/2a Clinical Data of VO659 in Treatment of Huntington’s Disease
Vico Therapeutics B.V. recently announced new positive interim data in Huntington’s disease (HD) from the ongoing Phase 1/2a clinical trial of VO659, an investigational allele-preferential…
Biosplice Therapeutics Announces Initiation of AML & MDS Trial Sponsored by the National Cancer Institute
Biosplice Therapeutics, Inc. recently announced the US FDA has cleared the NCI-sponsored Investigational New Drug (IND) application for cirtuvivint. This small molecule inhibitor of CLK…
Vironexis Biotherapeutics Launches With FDA Clearance of IND Application for First-Ever Clinical Trial of an AAV-delivered Cancer Immunotherapy
Vironexis Biotherapeutics launched from stealth, unveiling its TransJoin AAV Gene Therapy Platform and a pipeline of more than ten product candidates for blood-based cancers, solid…
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
Monopar Therapeutics Inc. recently announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial confirming MNPR-101-Zr’s tumor targeting ability…
Cellares & Sony Announce a Joint Development Collaboration to Integrate Flow Cytometry-Based Sorting & Online Analysis Into an Automated, High-Throughput Cell Therapy Manufacturing Platform
Cellares and Sony Corporation recently announced a collaboration to jointly develop and integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell…
